A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity

Clinical Cancer Research

Volumn 17, Issue 1, 2011, Pages 100-110

  Martin Killias, Patricia ^a   Stefan, Nikolas ^a   Rothschild, Sacha ^b,c   Plückthun, Andreas ^a   Zangemeister Wittke, Uwe ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; DESIGNED ANKYRIN REPEAT PROTEIN EC4; EPITHELIAL CELL ADHESION MOLECULE; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOPLASM; DRUG ACCUMULATION; DRUG BINDING; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG POTENCY; DRUG RESPONSE; DRUG TARGETING; EPITHELIUM CELL; ESCHERICHIA COLI; FEMALE; IC 50; IN VITRO STUDY; INJECTION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PURIFICATION; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR LOCALIZATION; TUMOR XENOGRAFT;

ADP RIBOSE TRANSFERASES; ANIMALS; ANKYRIN REPEAT; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL SURVIVAL; EXOTOXINS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PROTEIN ENGINEERING; PSEUDOMONAS AERUGINOSA; RECOMBINANT FUSION PROTEINS; VIRULENCE FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78751503899     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1303     Document Type: Article

References (43)

1. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-63.
2. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007;58:221-37.
3. Shimamura T, Husain SR, Puri RK. The IL-4 and IL-13 Pseudomonas exotoxins: new hope for brain tumor therapy. Neurosurg Focus 2006;20:E11.
4. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006;6:559-65.
5. Wolf P, Elsasser-Beile U. Pseudomonas exotoxin A: from virulence factor to anti-cancer agent. Int J Med Microbiol 2009;299:161-76.
6. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, et al. Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005;23:6719-29.
7. Kreitman RJ, Pastan I. Immunotoxins in the treatment of hematologic malignancies. Curr Drug Targets 2006;7:1301-11.
8. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant antimesothelin immunotoxin given as a bolus i.v. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-9.
9. Biggers K, Scheinfeld N. VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer. Curr Opin Mol Ther 2008;10:176-86.
10. Fuchs H, Bachran C. Targeted tumor therapies at a glance. Curr Drug Targets 2009;10:89-93.
11. Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D, Waibel R, et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 2003;9: 2837-48.
12. Hussain S, Plückthun A, Allen TM, Zangemeister-Wittke U. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol Cancer Ther 2007;6:3019-27.
13. Hussain S, Plückthun A, Allen TM, Zangemeister-Wittke U. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL. Mol Cancer Ther 2006;5:3170-80.
14. Winkler J, Martin-Killias P, Plückthun A, Zangemeister-Wittke U. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol Cancer Ther 2009;8:2674-83.
15. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999;77:699-712.
16. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009;11:162-71.
17. McLaughlin PM, Harmsen MC, Dokter WH, Kroesen BJ, Van Der Molen H, Brinker MG, et al. The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy. Cancer Res 2001;61:4105-11.
18. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004;35:122-8.
19. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000;356:1981-2.
20. Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Baeuerle PA, et al. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 2006;103:483-8.
21. Boman BM, Huang E. Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol 2008;26:2828-38.
22. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008;10:R25.
23. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-7.
24. Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 2010;52:280-1.
25. Ewert S, Honegger A, Plückthun A. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. Methods 2004;34:184-99.
26. Willuda J, Honegger A, Waibel R, Schubiger PA, Stahel R, Zangemeister-Wittke U, et al. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized antiepithelial glycoprotein-2 (epithelial cell adhesion molecule) singlechain Fv fragment. Cancer Res 1999;59:5758-67.
27. Binz HK, Amstutz P, Plückthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 2005;23:1257-68.
28. Binz HK, Stumpp MT, Forrer P, Amstutz P, Plückthun A. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol 2003;332:489-503.
29. Binz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, Forrer P, et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 2004;22:575-82.
30. Binz HK, Kohl A, Plückthun A, Gütter MG. Crystal structure of a consensus-designed ankyrin repeat protein: implications for stability. Proteins 2006;65:280-4.
31. Wels W, Harwerth IM, Mueller M, Groner B, Hynes NE. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res 1992; 52:6310-7.
32. Hansen RE, Ostergaard H, Norgaard P, Winther JR. Quantification of protein thiols and dithiols in the picomolar range using sodium borohydride and 4,4'-dithiodipyridine. Anal Biochem 2007;363:77-82.
33. Seetharam S, Chaudhary VK, FitzGerald D, Pastan I. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J Biol Chem 1991;266:17376-81.
34. von Minckwitz G, Harder S, Höelmann S, Jäger E, Al-Batran SE, Loibl S, et al. Phase I clinical study of the recombinant antibody toxin scFv (FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res 2005;7:R617-26.
35. Wörn A, Plückthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol 2001;305:989-1010.
36. Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, Nagy-Davidescu G, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010;70:1595-605.
37. Madshus IH, Collier RJ. Effects of eliminating a disulfide bridge within domain II of Pseudomonas aeruginosa exotoxin A. Infect Immun 1989;57:1873-8.
38. Manoukian G, Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther 2009;9:1445-51.
39. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology 2006;43:S45-53.
40. Mühlen KA, Schümann J, Wittke F, Stenger S, Van Rooijen N, Van Kaer L, et al. NK cells, but not NKT cells, are involved in Pseudomonas aeruginosa exotoxin A-induced hepatotoxicity in mice. J Immunol 2004;172:3034-41.
41. Wolf P, Gierschner D, Buhler P, Wetterauer U, Elsasser-Beile U. A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells. Cancer Immunol Immunother 2006;55:1367-73.
42. Mazor Y, Noy R, Wels WS, Benhar I. chFRP5-ZZ-PE38, a large IgGtoxin immunoconjugate outperforms the corresponding smaller FRP5 (Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts. Cancer Lett 2007;257:124-35.
43. Zielinski R, Lyakhov I, Jacobs A, Chertov O, Kramer-Marek G, Francella N, et al. Affitoxin-a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J Immunother 2009;32:817-25.